Vascarta Strengthens Leadership with Appointment of Dr. Janet Loesberg Vascarta has appointed Dr. Janet Loesberg as their Fractional Chief Strategy Officer, enhancing their strategic direction and portfolio management.

Vascarta Strengthens Leadership with Appointment of Dr. Janet Loesberg #United_States #Vascarta #Summit #Vasceptor #Dr._Loesberg

Vascarta's Vasceptor® Receives Key FDA Orphan Drug Status for Sickle Cell Treatment Vascarta Inc. has been granted Orphan Drug Designation for Vasceptor®, marking a significant advancement in treating Sickle Cell Disease.

Vascarta's Vasceptor® Receives Key FDA Orphan Drug Status for Sickle Cell Treatment #United_States #sickle_cell_disease #Vascarta #Summit #Vasceptor